Tivic Health Receives Second Global Health & Pharma Award: ClearUP Named 2022 Most Innovative Sinus Relief Solution
June 16 2022 - 12:00PM
Business Wire
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase
health technology company that develops and commercializes
bioelectronic medicine, today announced that for the second
consecutive year ClearUP® Sinus Pain Relief has received Global
Health & Pharma’s 2022 award for Most Innovative Sinus Relief
Solution. ClearUP is a small handheld device that is FDA-cleared,
CE marked, and clinically proven to provide relief from sinus pain
and congestion from allergies, colds, and flu.
The Global Health and Pharma Awards recognize businesses for
their excellent work in the healthcare and pharmaceutical sphere
and seek out businesses that are making a positive mark in the
world of health.
“Once again, I would like to thank the editors of Global Health
& Pharma for recognizing ClearUP’s benefits in the non-invasive
treatment of sinus pain,” said Jennifer Ernst, CEO of Tivic Health.
“As more consumers become leery about taking pharmaceutical drugs
to treat every day ongoing concerns like allergies and sinus
congestion, we are now seeing bioelectronic medicine emerge as a
natural alternative to pharmaceutical drugs. It is an honor to see
our platform technology awarded for a second year in a row. ClearUP
has been building confidence among users and health care
professionals for the treatment of sinus pain and congestion. We
are making continued progress with our bioelectronic platform
technology with the goal of developing alternative treatment
choices for consumers to help alleviate symptoms of other diseases
in the future, such as migraines.”
Sofi Bajor, editor, of Global Health & Pharma, said of Tivic
Health’s success, “GHP is proud to present Tivic Health with the
prestigious accolade of 2022’s Most Innovative Sinus Relief
Solution: ClearUP. Tivic Health not only has impressed us with its
technological innovation, but it has also left us in awe with its
fine customer service.”
Bioelectronic medicine was a topic of discussion at last month’s
Fortune Brainstorm Health conference, at which Jennifer Ernst
participated on a panel with Robert Ford, chairman and CEO of
Abbott, and Adrian Aoun, founder and CEO of Forward, examining how
new technologies, worldwide collaboration, evolving therapeutics
and big data drive better health outcomes and business value.
Today’s GHP award adds to a growing list of accolades for Tivic
Health, which was recently featured in Forbes, “Tivic Health Brings
Bioelectronics To Consumers Through Congestion Clearing,” and by
ABC News in “New Bioelectronic Technologies Could Signal the Future
of Medicine.” Previous awards for Tivic Health include ClearUP
being named to Fast Company’s Next Big Things in Tech, Innovation
& Tech Today’s Top 50 Most Innovative Health Tech Products,
TIME’s Most Innovative Products, and multiple Best of CES
awards.
About Tivic Health Systems, Inc.
Tivic Health Systems, Inc. is a commercial-phase health
technology company delivering non-invasive bioelectronic treatments
that provide consumers a choice in the treatment of inflammation
and related conditions. For more information visit
https://tivichealth.com @TivicHealth
Forward Looking Statements
This press release may contain “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
“will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on Tivic Health
Systems, Inc.’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to
predict. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Additional information concerning Tivic Health and its business,
including a discussion of factors that could materially affect the
company operating results, is contained in the company’s Annual
Report on Form 10-K for the year ended December 31, 2021, filed
with the Securities and Exchange Commission on March 31, 2022,
under the heading “Risk Factors,” as well as the Company’s
subsequent filings with the Securities and Exchange Commission.
Forward-looking statements contained in this press release are made
as of this date, and Tivic Health Systems, Inc. undertakes no duty
to update such information except as required by applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220616005753/en/
Media Contact: Tivic Health Cheryl Delgreco
Cheryl.Delgreco@tivichealth.com 617-429-6749 Investor
Relations: ir@tivichealth.com
Tivic Health Systems (NASDAQ:TIVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tivic Health Systems (NASDAQ:TIVC)
Historical Stock Chart
From Apr 2023 to Apr 2024